Unity Bio Stock (NASDAQ:UBX)
Previous Close
$0.97
52W Range
$0.85 - $3.10
50D Avg
$1.56
200D Avg
$1.47
Market Cap
$16.39M
Avg Vol (3M)
$228.18K
Beta
1.30
Div Yield
-
UBX Company Profile
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.
UBX Performance
Peer Comparison
| Ticker | Company |
|---|---|
| NUVB | Nuvation Bio Inc. |
| HRTX | Heron Therapeutics, Inc. |
| NXTC | NextCure, Inc. |
| RXRX | Recursion Pharmaceuticals, Inc. |
| EDIT | Editas Medicine, Inc. |
| WINT | Windtree Therapeutics, Inc. |
| BEAM | Beam Therapeutics Inc. |
| VERV | Verve Therapeutics, Inc. |
| RNA | Avidity Biosciences, Inc. |
| NTLA | Intellia Therapeutics, Inc. |
| AVIR | Atea Pharmaceuticals, Inc. |
| ENSC | Ensysce Biosciences, Inc. |
| PRME | Prime Medicine, Inc. |
| DRMA | Dermata Therapeutics, Inc. |
| HOOK | HOOKIPA Pharma Inc. |
| CNTB | Connect Biopharma Holdings Limited |
| OVID | Ovid Therapeutics Inc. |
| ABOS | Acumen Pharmaceuticals, Inc. |